TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06347861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment A)
Description: phase 3 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment B)
Description: registration tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment C)
Description: registration tablets
Study: NCT05045781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: single iv infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: single iv infusion
Study: NCT05032495

Intervention type: OTHER
Intervention: Surveys
Description: Surveys to evaluate prior experience, opinions and intervention acceptability.

Intervention type: OTHER
Intervention: Surveys
Description: Surveys to evaluate prior experience, opinions and intervention acceptability.

Intervention type: OTHER
Intervention: Surveys
Description: Surveys to evaluate prior experience, opinions and intervention acceptability.

Intervention type: OTHER
Intervention: Surveys
Description: Surveys to evaluate prior experience, opinions and intervention acceptability.

Intervention type: OTHER
Intervention: Focus group
Description: To answer any questions and discuss topics covered in the standard presentation.

Intervention type: OTHER
Intervention: Focus group
Description: To answer any questions and discuss topics covered in the standard presentation.

Intervention type: OTHER
Intervention: Focus group
Description: To answer any questions and discuss topics covered in the standard presentation.

Intervention type: OTHER
Intervention: Focus group
Description: To answer any questions and discuss topics covered in the standard presentation.
Study: NCT06056687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid 600 MG Oral Tablet
Description: Alpha Lipoic Acid 600 MG Oral Tablet once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily
Study: NCT05321069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06055413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) bundle
Description: Patient-families will be given a remote patient monitoring (RPM) bundle with tools to measure objective and subjective information about the child at home that are shared with the home ventilator provider team through an electronic dashboard. The tools include a device to measure carbon dioxide, a digital tablet, a digital weight scale, and a digital application that connects to the child's electronic health record. Each child will be assigned an individualized remote monitoring schedule (timing and data type) based on their indication for ventilation and ventilator regimen at enrollment.
Study: NCT06120569

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus ms exercise
Description: Soleus muscle exercise before and after eating by half an hour

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soleus ms exercise
Description: Soleus muscle exercise before and after eating by half an hour
Study: NCT04913155

Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose CT screening
Description: Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score

Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose CT screening
Description: Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score

Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose CT screening
Description: Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score

Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose CT screening
Description: Low-dose computed tomography with lung nodule evaluation (LungRADS1.1, highrisk score group), randomized reporting of coronary artery calcium score and emphysema score
Study: NCT05173168

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Dietary Supplement
Description: Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts
Study: NCT06204614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Micro-Device
Description: The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
Study: NCT05169515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Mosunetuzumab
Description: Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Glofitamab
Description: Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Study: NCT06135545

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome SAPB
Description: Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional TPVB
Description: The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
Study: NCT06651957

Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Specimen swabs will be obtained.

Intervention type: OTHER
Intervention: Questionnaires
Description: Given to participants
Study: NCT06319820

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAR-210
Description: TAR-210 will be administered intravesically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravesically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: MMC will be administered intravesically.
Study: NCT04816591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Interventional Cohort: Treatment Arm
Description: Standard of Care Surgery + Embolization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Interventional Cohort: Control Arm
Description: Standard of Care Surgery Only (Control)
Study: NCT05067348

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab Injectable Product
Description: Participants will receive IV tocilizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injectable Product
Description: Participants will receive IV tocilizumab
Study: NCT05870553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0301-A
Description: Bowel Preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0301-B
Description: Bowel Preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cool prep
Description: Bowel Preparation
Study: NCT06204614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be placed in reservoir 1 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be placed in reservoir 2 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be placed in reservoir 3 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be placed in reservoir 4 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine will be placed in reservoir 5 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin I
Description: Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin II
Description: Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be placed in reservoir 9 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be placed in reservoir 10 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin
Description: Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Vinblastine/Doxorubicin/Cisplatin
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin/Nivolumab
Description: (Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
Study: NCT04816591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: Observational Cohort: Treatment Arm
Description: Standard of Care Medical Management + Embolization
Study: NCT06204614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Docetaxel/Ifosfamide
Description: (Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
Study: NCT04816591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Observational Cohort: Control Arm
Description: Standard of Care Medical Management Only (Control)
Study: NCT06204471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helite hip protector
Description: hip protector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helite hip protector
Description: hip protector
Study: NCT05322850

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orca-Q
Description: All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
Study: NCT06204471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolk hip protector
Description: Hip protectdor
Study: NCT06204614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be placed in reservoir 17 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin/Nivolumab
Description: (Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab
Description: Enfortumab will be placed in reservoir 19 of the implantable microdevice.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab
Description: Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
Study: NCT05859269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone followed with a 6-day oral methylprednisolone taper course.~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care.
Study: NCT05037357

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma EBV DNA qPCR test
Description: Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
Study: NCT05859269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients will receive a single intraoperative dose of 10 mg intravenous dexamethasone (control group, IV dexamethasone is standard of care).~Patients will also receive a standardized multimodal postoperative pain management regimen which includes nonsteroidal anti-inflammatory medication (e.g., NSAIDs) and opioid pain medications, both in the hospital and at home as part of standard care.
Study: NCT06657690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
Study: NCT06221800

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Stool and saliva samples will be collected

Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Stool and saliva samples will be collected
Study: NCT06657690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
Study: NCT06661460

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Cognitive Behavioral Therapy
Description: The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
Study: NCT06659640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-6400
Description: ALN-6400 will be administered subcutaneously (SC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC)
Study: NCT06660563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-80948543
Description: JNJ-80948543 will be administered as subcutaneous (SC) or intravenous (IV) injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-75348780
Description: JNJ-75348780 will be administered as SC injection.
Study: NCT06662786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan hydrochloride will be administered as chemotherapy regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Irinotecan hydrochloride will be administered as chemotherapy regimen.
Study: NCT06665945

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet RNA expression
Description: The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet RNA expression
Description: The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet RNA expression
Description: The SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer.
Study: NCT06606860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel Pamoate tablet, 250mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxantel Pamoate
Description: Oxantel Pamoate tablet, 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT06669442

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: Guided imagery is a mindfulness based therapeutic technique that involves utilizing positive imagery allowing one to cultivate awareness of their mental state and shift their attention from ruminative thought patterns to the present moment. Evidence-based research shows that benefits of Guided imagery include relaxation, stress reduction, anxiety reduction, immune system enhancement, and overall well-being.
Study: NCT06670105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given by vein
Study: NCT06675162

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Reformer Training
Description: Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Reformer Training
Description: Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
Study: NCT05785455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COGMO Intervention
Description: Group sessions in which each patient, after motivational interviewing sessions will follow a goup education in pain neuroscince program followed by a cognition targeted exercise therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Primary Care health education and treatment for patients with chronic neck pain